TL;DR
Turn your wind-down time into listening time
- Thousands of audiobooks, podcasts and originals
- Listen on your phone, tablet or Echo — also offline
- Cancel anytime
University of Kentucky researchers reported that Alzheimer’s-model mice slept more than two additional hours per day after a drug temporarily depleted most of their microglia, brain immune cells. The study did not remove amyloid plaques, but it was conducted in mice; it does not establish a treatment for people with Alzheimer’s or show that the same result would occur in humans.
Researchers at the University of Kentucky reported that Alzheimer’s-model mice slept more than two additional hours per day after a drug temporarily depleted most of their brain’s microglia, without clearing amyloid plaques. The findings, published in Alzheimer’s & Dementia, point to inflammation driven by these immune cells as a possible contributor to disrupted sleep, but they do not show that the approach works in people.
The research team studied mice genetically predisposed to develop amyloid plaques and compared them with normally aging mice. They examined animals at six months, when plaques first appeared in the model, and at 18 months, when its Alzheimer’s-like changes were more advanced. Sleep was measured with devices recording electrical activity in the brain and muscles, allowing the researchers to distinguish sleep stages.
To test whether microglia were involved in sleep disruption, the researchers gave the mice pexidartinib, also called PLX3397, in their food for 14 days. The drug blocks a signal microglia rely on for survival. After treatment, about 87% of the cells had been depleted, according to the report. The mice then slept longer and spent more time in deep, restorative sleep, while their amyloid plaques remained.
The result is an experimental finding, not evidence that removing microglia is safe or beneficial as a human treatment. Microglia also carry out normal protective and maintenance functions in the brain. The supplied report does not provide the full study’s group sizes, exact sleep-stage measurements, or details of how long the sleep changes lasted after treatment.
Sleep Improved Without Plaque Removal
The study challenges the idea that sleep disruption in Alzheimer’s-like disease is explained only by plaque deposits or damaged neurons. Its findings suggest that the immune response to plaques may also affect sleep, potentially by producing inflammation that alters normal brain activity. If further research supports this mechanism, it could broaden the range of biological processes researchers investigate when studying Alzheimer’s-related sleep problems.
That possibility remains far from a treatment recommendation. Depleting most microglia is a substantial intervention in a mouse experiment, and the cells have roles beyond inflammation. The findings do not show that reducing microglia in people would improve sleep, slow Alzheimer’s disease, or be safe. For readers, the immediate significance is a new line of research into a symptom that can have serious effects on patients and caregivers, not a proven way to restore sleep.
comfortable sleep mask blackout adjustable
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
How Researchers Tested the Sleep Link
Microglia are immune cells found in the central nervous system. They help clear debris and respond to threats, including amyloid plaques, a characteristic feature of Alzheimer’s disease. The researchers’ proposed explanation is that an excessive inflammatory response by microglia may disrupt sleep, rather than plaques alone accounting for the change. This is the interpretation tested by the cell-depletion experiment; it should not be treated as an established explanation for sleep problems in people.
The team used brain and muscle recordings to track sleep, and light-sheet microscopy to map plaques and microglia across brain tissue. Comparing the genetically modified mice with normally aging animals at two ages helped the researchers distinguish disease-model changes from age-related changes. The report identifies the study leaders as Shannon L. Macauley, an associate professor at the University of Kentucky College of Medicine, and first author Nicholas J. Constantino, a recent doctoral graduate.
“Basically, we showed that it is not the plaques themselves, or solely dysfunctional neurons, that cause sleep loss but actually microglia.”
— Shannon L. Macauley, associate professor at the University of Kentucky College of Medicine
As an affiliate, we earn on qualifying purchases.
Human Effects Remain Unknown
The reported experiments involved mice, not people. It is not yet clear whether the same microglia-related process contributes to sleep loss in human Alzheimer’s disease, or whether the sleep improvement would occur in a clinical setting. The report also does not establish how long the effect lasted, whether it could be achieved without broadly depleting microglia, or what risks such an intervention might carry.
The result does not mean that plaques are unimportant or that removing microglia reverses Alzheimer’s disease. Plaques remained in the treated mice, and the reported outcome was sleep. The supplied material does not give enough detail to assess the full study design, statistical strength, or possible effects beyond the reported sleep measures. Those details matter before the finding can be judged as a basis for further treatment research.
sleep diary journal for tracking sleep patterns
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Evidence Needed Beyond Mouse Models
The next step is further research to test the proposed link between microglia, inflammation and sleep, including whether it can be confirmed in other studies and whether comparable mechanisms appear in people. Researchers would also need to establish how the sleep effects relate to the duration and extent of microglia depletion, and whether there are safer ways to influence the inflammatory response without removing cells that help protect the brain.
The report does not identify a human trial, a planned clinical study, or a timeline for one. Until additional evidence is available, the finding should be understood as a preclinical result that may guide investigation of Alzheimer’s-related sleep disruption, rather than a new therapy for patients.
bedside clock with dimmable display
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Key Questions
What did the researchers find?
In Alzheimer’s-model mice, sleep increased by more than two hours per day after treatment temporarily depleted most microglia. The mice also spent more time in deep sleep, according to the report.
Were the amyloid plaques removed?
No. The reported sleep improvement occurred without clearing the amyloid plaques. The researchers focused on reducing microglia, the immune cells that respond to plaques.
Does this mean there is a new Alzheimer’s treatment?
No. The study was conducted in mice and does not establish that microglia depletion would improve sleep or be safe in people. It is a research finding, not a proven treatment.
What drug did the team use?
The researchers used pexidartinib, or PLX3397, in the mice’s food for 14 days. The drug blocks a signal microglia need to survive; the report says about 87% of the cells were depleted.
What remains unknown?
It is not clear whether the same mechanism operates in human Alzheimer’s disease, how long the sleep effect lasts, or whether an approach affecting microglia could be made safe. The supplied report does not state that human trials are underway.
Source: hn
Halloween Picks
halloween
As an affiliate, we earn on qualifying purchases.
